Daiichi Sankyo Europe, GmbH
Clinical trials sponsored by Daiichi Sankyo Europe, GmbH, explained in plain language.
European subsidiary of Daiichi Sankyo, a global pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Thousands tracked: does bempedoic acid work in real life? Results expected Oct 2026 (estimated)
- New drug under Real-World watch for tough stomach cancer Results expected Dec 2026 (estimated)
- New triple therapy shows promise for stubborn high cholesterol Results expected Jul 2027 (estimated)
-
New drug under Real-World watch for tough stomach cancer
Disease control OngoingThis study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Thousands tracked: does bempedoic acid work in real life?
Knowledge-focused OngoingThis study is observing 5000 adults with high cholesterol who are taking bempedoic acid (alone or with ezetimibe) as part of their normal medical care. Researchers will collect data on cholesterol levels, heart events, side effects, and quality of life over one year. The goal is …
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC